Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2

Sabari Nath Neerukonda1, Russell Vassell1, Rachel Herrup1, Shufeng Liu1, Tony Wang1, Kazuyo Takeda2, Ye Yang3, Tsai-Lien Lin3, Wei Wang1*, Carol D. Weiss1*

1 US Food and Drug Administration, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research and Review, Silver Spring, Maryland, United States of America, 2 US Food and Drug Administration, Office of Blood Research and Review, Center for Biologics Evaluation and Research and Review, Silver Spring, Maryland, United States of America, 3 US Food and Drug Administration, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research and Review, Silver Spring, Maryland, United States of America

* wei.wang@fda.hhs.gov (WW); carol.weiss@fda.hhs.gov (CDW)

Abstract

Pseudoviruses are useful surrogates for highly pathogenic viruses because of their safety, genetic stability, and scalability for screening assays. Many different pseudovirus platforms exist, each with different advantages and limitations. Here we report our efforts to optimize and characterize an HIV-based lentiviral pseudovirus assay for screening neutralizing antibodies for SARS-CoV-2 using a stable 293T cell line expressing human angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2). We assessed different target cells, established conditions that generate readouts over at least a two-log range, and confirmed consistent neutralization titers over a range of pseudovirus input. Using reference sera and plasma panels, we evaluated assay precision and showed that our neutralization titers correlate well with results reported in other assays. Overall, our lentiviral assay is relatively simple, scalable, and suitable for a variety of SARS-CoV-2 entry and neutralization screening assays.

Introduction

In December 2019 a cluster of atypical pneumonia cases appeared in Wuhan, China. The etiological agent was later identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) [1–4]. In the past year, SARS-CoV-2 spread as a global pandemic with more than 75 million cases and 1.6 million deaths (Source: Johns Hopkins Coronavirus Resource Center; https://coronavirus.jhu.edu/). A key priority in fighting the ongoing pandemic involves measuring immune responses to the spike (S) glycoprotein of SARS-CoV-2, a critical target for developing preventive vaccines [5] and antibody (Ab)-based therapeutics for COVID-19 patients [6,7], including therapeutic monoclonal antibodies (mAbs) and convalescent plasma therapy [8–16].
Assessments of serological responses to the S glycoprotein typically include virus microneutralization (MN) assays or enzyme-linked immunosorbent assay (ELISA), and ELISA variants, such as lateral flow assay (LFA), chemiluminescence immunoassay (CLIA), and electrochemiluminescence immunoassay (ECLIA) [17–19]. Replicating, wild-type (WT) SARS-CoV-2 MN assays remain the gold standard, but they are labor intensive due to the need for high biosafety level containment (BSL-3) handling by trained personnel and challenges for high throughput [20]. On the other hand, ELISA formats are safe and high throughput, but they do not always measure titers that strongly correlate with neutralization titers measured in the WT MN assay [10,18,21–23]. Neutralizing Abs are thought to be an important component of protection. Some Abs that bind to S in ELISAs do not neutralize virus because they bind to S epitopes that do not interfere with receptor binding or fusion steps needed for virus entry [24–26].

The trimeric S glycoprotein mediates virus entry by binding to the ACE2 receptor on target cells and catalyzing fusion between viral and target cell membranes. Proteolytic processing of S is required for its fusion competence. The multi-basic furin-like cleavage site (RRAR•SV) allows S to be efficiently cleaved into the S1 subunit that contains the receptor binding domain (RBD) and the S2 subunit that contains domains needed for fusion [27–29]. Efficient entry into the target cells additionally requires S protein priming at the S2’ site by cellular proteases, such as TMPRSS2 or cathepsins B and L (Cat B or L) [28]. Depending upon the cell type, cellular proteases promote entry at the cell surface (e.g., TMPRSS2 in lung epithelium and TMPRSS4 in gut enterocytes) or in endosomes (e.g., Cat L) [28,30]. Small molecules or other inhibitors that target the S protein fusion function or cellular proteases needed for S2’ priming prevent the fusion step of entry [28]. Neutralizing Abs directed against the top of the RBD typically compete with virus binding to ACE2, while those directed against the side surfaces of the RBD often do not efficiently compete with ACE2 binding and may therefore show less potent neutralization [17].

Pseudoviruses bearing viral envelope proteins provide safe surrogates for highly pathogenic viruses in MN assays. Several groups have generated SARS-CoV-2 pseudoviruses with glycoprotein defective murine leukemia virus (MLV)-, human immunodeficiency virus (HIV)-, and vesicular stomatitis virus (VSV)-based systems and used them in neutralization assays based on fluorescence (monomeric Neon Green or mNG) or enzymatic activity (nano-, gaussia-, and firefly luciferases) read outs in a variety of target cell types [20,24,31–44]. In the present study, we describe our optimized conditions for an HIV-based lentiviral SARS CoV-2 pseudovirus neutralization assay. To resemble respiratory cells with TMPRSS2 and facilitate assay procedures, we established a stable 293T cell line expressing both ACE2 and TMPRSS2. We present our detailed methodology and the performance characteristics of the assay, which should be suitable for many quantitative, high-throughput virus neutralization and entry screens that can be easily performed in a BSL-2 laboratory.

Materials and methods

Ethics statement

This study did not require full FDA IRB review and approval because it was deemed (2020-CBER-139) as “not research involving human subjects” as defined in 45 CFR part 46, and it is not an FDA-regulated clinical investigation as defined in 21 CFR part 56.

Plasmids, cell lines, and inhibitors

Full-length open reading frame of the S gene of SARS-CoV2 Wuhan-Hu-1 isolate (Genbank accession: YP_009724390.1) was synthetized by GenScript (Piscataway, NJ) and cloned into the pCMV/R expression plasmid. Mutations in S were introduced using standard molecular
biology protocols and confirmed by sequencing. The HIV gag/pol (pCMVΔR8.2), pCMV/R, and Luciferase reporter (pHR’CMV-Luc) plasmids described previously [45,46] were obtained from the Vaccine Research Center (National Institutes of Health (NIH), Bethesda, MD). pCAGGS-TMPRSS2 plasmid [47] was obtained from Dr. Mikhail Matrosovich (University of Marburg, Germany). pHAGE2-EF1αnt-TMPRSS2-IRE5-mCherry plasmid was obtained from Dr. Jesse Bloom (Fred Hutchinson Cancer Center, Seattle, WA) [48]. pCMV-VSV-G was obtained from Dr. Kathy Bouir, (University of California, San Diego). A plasmid encoding human ACE2 (hACE2-TM) was obtained from the NIH Vaccine Research Center. HEK293-T-ACE2 (293T.ACE2s) cells stably expressing ACE2 were obtained through BEI Resources, National Institute of Allergy and Infectious Diseases, NIH; (NR-52511, contributed by Jesse Bloom, Fred Hutchinson Cancer Research Center, Seattle, WA) [32]. The 293T, Vero, Vero E6, A549, Caco-2, Calu-3 and Huh-7 cells were maintained at 37˚C in Dulbecco’s modified eagle medium (DMEM) supplemented with high glucose, L-Glutamine, minimal essential media (MEM) non-essential amino acids, penicillin/streptomycin and 10% fetal bovine serum (FBS). Chemical inhibitors, camostat mesylate (TMPRSS2 inhibitor; Cat no: SML0057) and chloroquine (endosomal acidification inhibitor; Cat no: 50-63-5) were obtained from MilliporeSigma.

Antibodies and sera

Mouse mAb 10G6H5 against SARS-COV2 S protein was purchased from GenScript (Piscataway, NJ). Rabbit antisera against the S1 subunit, the receptor binding domain (RBD), and the S2 subunit of SARS-COV2 S protein [49] were provided by Surender Khurana (US Food and Drug Administration, Silver Spring, MD). The National Institute of Biological Standards and Control (NIBSC) serology reference panel, including 20/120, 20/122, 20/124, 20/126, 20/128 and 20/130, against SARS-COV-2 was provided by Giada Mattiuzzo (National Institute for Biological Standards and Control (NIBSC), Potters Bar, UK). Human plasma from COVID-19 patients were provided by James Rost and Norton Elson (Washington Adventist Medical Healthcare), Nicholas Cacciabeve (Advanced Pathology Associates), and Rob San Luis, Hollie Genser, Demetra Collier, Meaza Belay, Genevieve Caoli, Zanetta E. Morrow, and Bruana Streets (Quest Diagnostics). A serum and plasma proficiency panel (focused concordance samples) with high, medium, and low neutralizing titers against SARS-COV-2 and a blinded serum and plasma panel developed for the SARS-CoV-2 neutralization assay concordance survey (SNACS) were provided by Dr. David Montefiori (Duke University, Durham, NC). Negative control sera collected in September-December of 2009 from 45 volunteers ages 48–64 years was described previously [50]. HIV-1 p24 hybridoma (183-H12-5C) was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH and contributed by Dr. Bruce Chesebro.

Pseudovirus production and neutralization

Pseudoviruses bearing the S glycoprotein and carrying a firefly luciferase (FLuc) reporter gene were produced in 293T cells. Briefly, 5µg of pCMVΔR8.2, 5µg of pHR’CMVLuc and 0.5µg of S or its mutants (codon optimized) expression plasmids with or without 2µg of the TMPRSS2 expression plasmid were co-transfected in 293T cells. Pseudovirus supernatants were collected approximately 48 h post-transfection, filtered through a 0.45µm low protein binding filter, and used immediately or stored at -80˚C. Pseudovirus titers were measured by infecting different cells for 48 h prior to measuring luciferase activity (luciferase assay reagent, Promega, Madison, WI), as described previously [51]. Pseudovirus titers were expressed as relative luminescence unit per milliliter of pseudovirus supernatants (RLU/ml).
Neutralization assays were performed on 293T cells transiently transfected or transduced with ACE2 and TMPRSS2 genes for stable expression. Briefly, pseudoviruses with titers of approximately $10^6$ RLU/ml of luciferase activity were incubated with antibodies or sera for one hour at 37˚C. Pseudovirus and antibody mixtures (100 μl) were then inoculated onto 96-well plates that were seeded with $3.0 \times 10^4$ cells/well one day prior to infection. Pseudovirus infectivity was scored 48 h later for luciferase activity. The antibody dilution or mAb concentration causing a 50% and 80% reduction of RLU compared to control (ID$_{50}$ and ID$_{80}$ or IC$_{50}$ and IC$_{80}$, respectively) were reported as the neutralizing antibody titers. Titers were calculated using a nonlinear regression curve fit (GraphPad Prism software Inc., La Jolla, CA). The mean 50% and 80% reduction of RLU compared to control from at least two independent experiments was reported as the final titer. For experiments involving camostat mesylate (0.03–500 μM) and chloroquine (0.39–25 μM), target cells were treated with each inhibitor for two hours before pseudovirus infection in the presence of respective inhibitor.

**Generation of transient and stable 293T-ACE2.TMPRSS2 cells**

The 293T-ACE2.TMPRSS2$_{s}$ cells transiently expressing low, medium, and high levels of TMPRSS2 were generated by co-transfection of ACE2-TM and pCAGGS-TMPRSS2 plasmids in 2μg, 4μg and 8μg, respectively. Cell surface expression levels of ACE2 and TMPRSS2 were determined by flow cytometry. Briefly, transfected cells were harvested using non-enzymatic cell dissociation solution (Sigma-Aldrich) and resuspended in flow cytometry staining buffer (FCSB), PBS containing 2% FBS and 0.1% sodium azide, at $10^7$ cells/ml. Cells were incubated in AF647-conjugated anti-ACE2 mAb (Santa Cruz: sc-390851) and/or AF488 conjugated anti-TMPRSS2 mAb (Santa Cruz: sc-515727), followed by three FCSB washes. Cells were then fixed in 2% formaldehyde, washed with FCSB and quantified for signal intensity using a BD LSRFortessa-X20 flow cytometer (Becton Dickinson).

To generate stable 293T-ACE2.TMPRSS2$_{s}$ cells, VSV-G-pseudotyped lentiviruses carrying the human TMPRSS2 gene were generated by co-transfecting 293T cells with the pHAGE2-EF1Int-TMPRSS2-IRE5-mCherry, pCMVΔ8.2, and pCMV-VSV-G plasmids. Packaged lentivirus was used to transduce 293T-ACE2 cells in the presence of 10μg/mL polybrene, and the resulting bulk transduced population was single-cell sorted into clear bottomed 96 well plates by flow cytometry that was based on intermediate or high mCherry positivity on a BD FACSAria II Cell Sorter. Once single cell clones reached confluence, they were screened for mCherry/TMPRSS2 expression via EVOS Floid cell imaging station (Thermo Fisher, Waltham, MA), and several clones with visible mCherry expression were expanded. For verifying mCherry expression via flow cytometry, cells were harvested with enzyme-free cell dissociation buffer (Thermo Fisher, Waltham, MA), washed, and resuspended in FACS buffer. One clone that displayed intermediate levels of mCherry expression and maximum pseudovirus infectivity titer was selected and referred to as 293T-ACE2.TMPRSS2$_{s}$. Up to the present, this clone has supported high-level infectivity of SARS-CoV-2 pseudoviruses through 20 passages. This cell clone is deposited in BEI resources under the item number NRS-55293.

**SARS-CoV-2 mNG infection and confocal microscopy**

Vero E6 cells, 293T-hACE2$_{s}$, and 293T-ACE2.TMPRSS2$_{s}$ cells were seeded on poly-L-lysine-coated coverslips one day prior to infection. Infection with replicating SARS-CoV-2-mNG (MOI:0.1) was carried out in medium containing 2% FBS for one hour at 37˚C, prior to washing the cells twice with PBS and then maintaining in culture, described above. SARS-CoV-2-mNG expressing mNeon Green (mNG) in place of ORF7 was described previously [52]. At 24 h post infection (p.i.) SARS-CoV-2-mNG-infected coverslips were fixed with 4%
paraformaldehyde in PBS at room temperature for 20 min followed by PBS washes. SARS-CoV-2-mNG infection and fixing procedures were performed in a BSL-3 laboratory at the US Food and Drug Administration. Coverslips were counterstained with Hoechst 33258 dye (Thermo Scientific) and mounted on microscope slides with Fluoromount-G (SouthernBiotec). Confocal microscopy was performed by using SP8 DMi6000 confocal microscope (Leica Microsystems Inc, Germany) equipped with 25x water immersion objective lens and 405, 488 and 594 laser lines for Hoechst, mNG and mCherry signal, respectively.

**Immunoblot analysis**

Pseudoviruses were resolved by SDS-PAGE and detected by Western blot using a mouse mAb (183-H12-5C) against HIV-1 p24 Gag and rabbit antisera against the S1 subunit and the S2 subunit of SARS-COV-2 S protein.

**Statistics analysis**

To evaluate assay precision, six NIBSC plasma standards, 15 focused concordance samples and 21 SNACS samples were tested by three operators. Two operators ran four independent experiments (two independent experiments per operator), and a third operator ran one experiment. Titers were calculated from curves using eight dilutions. Intermediate precision, expressed as the percent coefficient of variation (%CV), was assessed separately for ID<sub>50</sub> and ID<sub>80</sub> titers. Sample dilutions with observed titers of less than 1:40 were considered as negative for antibodies to SARS-CoV-2 and were imputed a value of 1:20. An exploratory analysis was additionally performed by excluding titers of less than 1:40. Samples with more than 50% of less than 1:40 were excluded from all analyses. The total %CV accounts for both inter-operator and inter-assay variability and were estimated as follows based on a linear mixed model of the natural log-transformed titers with sample as a fixed effect and operator as a random effect:

\[
\%CV = \sqrt{\hat{\sigma}_{op}^2 + \hat{\sigma}_{is}^2} - 1 \times 100
\]

where \(\hat{\sigma}_{op}^2\) and \(\hat{\sigma}_{is}^2\) were the estimated inter-operator and inter-assay (within-operator) variance components from the model, respectively. SAS version 9.4 was used to perform the linear mixed model analysis.

To evaluate accuracy, since the true titers of test samples are not known, the Spearman correlation coefficient between the reported titers and the "observed" titers was estimated with GraphPad Prism software.

**Results and discussion**

**Selection of optimal target cells for SARS-CoV-2 pseudovirus infectivity**

We generated SARS-CoV-2 pseudoviruses bearing full-length S glycoprotein from the SARS-CoV-2 Wuhan-Hu-1 isolate using a second-generation lentiviral packaging system that we used previously for producing pseudoviruses bearing other viral glycoproteins [51,53,54]. We assessed SARS-CoV-2 pseudoviruses for infectivity in target cell types that were previously reported to support various levels of pseudovirus and replicating virus infectivity. A previous study reported higher infectivity of VSV-based pseudoviruses in Huh7, 293T, and Vero cells compared to CHO, MDCK, and HepG2 cells [39], but other studies reported poor or no infectivity of 293T cells due to the absence of ACE2 receptor [33,43]. Other cell types, including stably engineered cells (293T, 293T17, HT1080, BHK21), transiently transfected cells (293T, Caco-2, Huh7, HepG2, MDCK), and various continuous cell lines (Vero-E6, A549, BEAS2B, Calu-3, H1299, MRC5, Caco-2, HeLa, K562) that express ACE2, TMPRSS2, or both, have been
widely reported to support pseudovirus infectivity to different degrees [20,24,31–44]. We therefore assessed a panel of cell types, including Vero, Vero E6, A549, Caco-2, Calu-3, HuH7, 293T, and 293T cells transiently expressing ACE2 (293T-ACE2<sub>t</sub>), TMPRSS2 (293T-TMPRSS2<sub>t</sub>), or both (293T-ACE2.TMPRSS2<sub>t</sub>), to identify the cells that supported the highest levels of infectivity for our pseudoviruses.

As expected, our SARS-CoV-2 pseudoviruses lacked infectivity above background levels (approximately 10<sup>4</sup> RLU/ml) in 293T cells due to the absence of the ACE2 receptor, while Vero-E6 cells are naturally resistant to human lentivirus infection due to intrinsic restriction factors (Fig 1A). The A549, Caco-2, Calu-3, and HuH-7 cells also lacked infectivity above background levels (Fig 1A). Transient 293T-TMPRSS2<sub>t</sub> or 293T-ACE2<sub>t</sub>, cells had 5.7- and 40-fold signal above background, respectively, while transient 293T-ACE2.TMPRSS2<sub>t</sub> cells resulted in a 3130-fold signal above background (Fig 1A). A stable 293T-ACE2<sub>s</sub> cell line displayed 144-fold higher signal compared to background (Fig 1A).

A prior report demonstrated priming of SARS-CoV-2 S in VSV-based pseudoviruses by TMPRSS2-related proteases TMPRSS11D, 11E, 11F, and 13 in Calu-3 target cells. Of the...
TMPRSS2-related proteases, TMPRSS13 was as efficient as TMPRSS2, while the others were less efficient in promoting S priming and thus infectivity [41]. In the present study, we investigated the ability of TMPRSS11D (also known as human airway trypsin) in target 293T cells transiently expressing ACE2 and TMPRSS11D (293T-ACE2.TMPRSS11D). Consistent with the prior report, TMPRSS11D was less efficient in S priming, as reflected by an 11-fold lower infectivity in 293T-ACE2.TMPRSS11D cells compared to 293T-ACE2.TMPRSS2 cells (Fig 1A).

To facilitate SARS-CoV-2 pseudovirus neutralization assays and partly mimic natural SARS-CoV-2 target cells that express TMPRSS2, we established a stable cell line expressing both ACE2 and TMPRSS2 (293T-ACE2.TMPRSS2S) by transducing the 293T-ACE2 cells with a lentivirus encoding TMPRSS2 and mCherry as a bicistronic transcript. The ACE2.TMPRSS2S cells conferred infectivity approximately 1700-fold above background, confirming the contribution of TMPRSS2 protease activity for priming the S protein for fusion competence. Our findings agree with a recent study reporting that TMPRSS2 enhances SARS-CoV-2 pseudovirus entry and that S activation by TMPRSS2 correlates with the presence of the multi-basic furin cleavage site [55]. Because the ACE2.TMPRSS2S cells facilitated greater levels of infectivity and provided > 10^8 RLU/ml infectivity (>3 log range) for resolving titers, we focused on qualifying the 293T-ACE2.TMPRSS2S cells for our future studies. We also confirmed S protein incorporation into pseudoviruses and proteolytic processing of the S protein to generate S1 and S2 subunits that migrate at 130 kDa and 75 kDa, respectively (Fig 1B and Supporting Information).

**Optimization of SARS-CoV-2 pseudovirus infectivity**

We investigated several conditions for optimizing SARS-CoV-2 pseudovirus production in 293T cells. When comparing S priming by TMPRSS2 during pseudovirus production to priming during entry into target cells, we found that co-expressing TMPRSS2 during pseudovirus production reduced pseudovirus infectivity, possibly due to TMPRSS2-induced premature activation of S that promotes conformational changes to fusion-incompetent or post-fusion structures (Fig 1C). This finding is consistent with a previous report suggesting the importance of tight regulation of protease cleavage of the S protein for preserving SARS-CoV-2 infectivity [56].

We also investigated variant S proteins to further optimize pseudovirus production. We generated S genes with the D614G mutation or a C-terminal cytoplasmic tail truncation of 19 amino acids (TR19) that were previously reported to yield higher infectivity titers compared to full length WT S glycoprotein [34,38,39,42,57]. The D614G change represents a natural mutation outside RBD that became dominant in the circulating strains [39]. In 293T-ACE2, cells, the D614G mutation was reported to confer 1-log or >1/2-log higher infectivity to VSV-based or lentivirus-based S pseudoviruses, respectively [38,39,58]. Furthermore, viruses with the G614 S were associated with higher virion stability and increased in vitro SARS-CoV-2 replication fitness in primary human airway epithelial cells and Calu-3 cells [58]. Increased infectivity conferred by the D614G change is due to removal of hydrogen-bond interaction with T859 from a neighboring protomer of the S trimer. This results in an allosteric change of RBD domain to an “up” conformation that facilitates ACE2 receptor binding that may make the virus modestly more susceptible to neutralization by some sera or antibodies, depending the epitopes targeted by the antibodies [39,57,58]. Truncation of C-terminal 18 or 19 amino acids, which removes a putative ER retention signal, was also demonstrated to enhance HIV-based pseudotyping efficiency by 10-fold compared to WT S protein in 293T-ACE2, cells [42,59]. The higher infectivity conferred by the C-terminal cytoplasmic tail truncation of 19 amino acids may be due to higher number of infectious particles [42].

Consistent with previous reports, we found that pseudoviruses bearing G614 and TR19 S proteins displayed 0.5- and 0.2-log higher infectivity, respectively, compared to WT
pseudovirus in 293T-ACE2, cells (Fig 1D). Pseudoviruses with TR14 S had slightly lower infectivity compared to WT pseudoviruses (Fig 1D). However, in 293T-ACE2.TMPRSS2, cells the pseudovirus bearing the G614 S and TR19 S were more similar to WT S pseudoviruses, but the pseudovirus bearing the TR14 S displayed 0.5 log lower infectivity compared to WT pseudovirus (Fig 1D). Infectivity titers of all pseudoviruses were 1–1.5-log lower on 293T-ACE2, cells compared to 293T-ACE2.TMPRSS2, cells (Fig 1D). Based on these studies, we used WT S to qualify our pseudovirus neutralization assay because it represents the native, full-length spike, and the infectivity of WT S pseudoviruses give a large dynamic range for generating neutralization dose-response curves. Additional efforts to enhance pseudovirus infectivity with polybrene, a polycation that is known to enhance lentiviral transduction efficiency by minimizing charge-repulsion between the virus and cells, displayed no effect on pseudovirus infectivity.

Replication of SARS-CoV-2-mNG in 293T-ACE2.TMPRSS2, cells

We confirmed the acceptability of the 293T-ACE2.TMPRSS2, cells for SARS-CoV-2 infectivity and neutralization studies by assessing how well the cells support infection by replicating SARS-CoV-2. We compared replication levels and cytopathic effects (CPE) in 293T-ACE2. TMPRSS2, to Vero E6 cells that are widely used for the propagation of SARS-CoV-2, as well as to 293T-ACE, cells that lack TMPRSS2. Typically, SARS-CoV-2 induces CPE in Vero cells by 48–72 h post infection (p.i.), characterized by cell rounding, detachment, degeneration, and syncytia [60]. However, by 24 h p.i., when both SARS-CoV-2-infected Vero E6 and 293T-ACE2, cells began to display mNG expression and early CPE, SARS-CoV-2-infected 293T-ACE2.TMPRSS2, cells displayed robust mNG expression and higher levels of CPE with nearly 50% of infected monolayer undergoing detachment (Fig 2). The rapid kinetics of infection is consistent with a study indicating co-expression of ACE2 and TMPRSS2 synergistically increases SARS-CoV-2 or pseudovirus entry efficiency and another study showing that SARS--CoV-2-infected Vero E6/TMPRSS2 cells displayed rapid infection kinetics and higher viral yield compared to Vero E6 cells [40,61]. The comparatively slower kinetics of infection observed in SARS-CoV-2-infected Vero E6 and 293T-ACE2, cells in the absence of TMPRSS2 suggests less efficient entry via the endosomal pathway [55].

Entry pathways of SARS-CoV-2 pseudoviruses

Next, we used chemical inhibitors to determine the protease that primes SARS-CoV-2 S protein for membrane fusion during pseudovirus entry in 293T-ACE2.TMPRSS2, cells. SARS-CoV-2 can use pH-dependent and -independent pathways for cell entry [62]. In cells lacking TMPRSS2, SARS-CoV-2 relies on endosomal-pH-dependent cysteine protease, such as cathepsin L for S priming, while entry is predominantly dependent on priming by TMPRSS2 in natural airway cells, such as lung epithelial cells, type II pneumocytes [62,63]. We found that pseudovirus entry into 293T-ACE2, cells, which lack TMPRSS2, was sensitive to the endosomal pH acidification inhibitor chloroquine, with a half maximal inhibitory concentration [IC50] of 0.79μM, but relatively insensitive to a TMPRSS2 inhibitor camostat mesylate. In contrast, pseudovirus entry was sensitive to camostat mesylate [IC50: 0.88μM] in 293T-ACE2.TMPRSS2, cells, but much less so to chloroquine treatment (Fig 3). Thus, SARS-CoV-2 predominantly uses TMPRSS2 for priming S during virus entry into the 293T-ACE2.TMPRSS2, cells.

Optimization of SARS-CoV-2 pseudovirus inoculum for neutralization assays

We next determined the inoculum range that would assure consistent neutralization titers according to the law of mass action [64]. Serial dilutions of rabbit serum or mAb (10G6H5)
were mixed with four different pseudovirus inoculums over a three-log range, prior to incubation with 293T-ACE2.TMPRSS2 cells (Fig 4). Although 100% neutralization was achieved at high serum or mAb concentrations using a relatively low inoculum of \(2 \times 10^4\) relative luciferase units/ml (RLU/ml), the dose-response curve displayed high variation at higher dilutions, precluding generation of a reliable curve for calculating 50% neutralization titers (Fig 4A and 4B). However, inoculums in the \(4 \times 10^5\)–\(1.4 \times 10^7\) RLU/ml range generated overlapping curves with little variation (Fig 4C and 4D). These dose-response curves yielded 50% neutralization titers with serum inhibitory dilution (ID\(_{50}\)) and mAb inhibitory concentration (IC\(_{50}\)) values that varied less than 2-fold over all pseudovirus inoculums. Therefore, inoculums of \(5 \times 10^5\)–\(1 \times 10^7\) RLU/ml were used for the neutralization assay.

**Assessment of the influence of ACE and TMPRSS2 levels on neutralization titers**

Because the 293T-ACE2.TMPRSS2 cells may have higher levels of TMPRSS2, ACE2, or both, compared to some primary airway cells, we explored whether different levels of ACE2 and TMPRSS2 on target cells might influence neutralization titers. We transiently transfected 293T cells with ACE2 and TMPRSS2 to achieve low, medium, and high levels of ACE2 and...
Expression levels of ACE2 and TMPRSS2 were confirmed via flow cytometry (Fig 5). Transfection of a higher plasmid concentration of ACE2 and TMPRSS2 resulted in an increase in the number of ACE2⁺/TMPRSS2⁺ cells (Fig 5A) as well as cell surface expression (Fig 5B and 5C). Neutralization assays performed with rabbit sera against RBD or S1 subunit, murine mAb 10G6H5, as well as an NIBSC reference plasma (#20/130), showed no significant differences in neutralization titers among the target cells with different levels of ACE2 and TMPRSS2 (Table 1). Neutralization ID₅₀ titers of rabbit sera against RBD and S1 subunit ranged from 9377 to 10540 and 5462 to 6742, respectively. NIBSC reference plasma ID₅₀ titers ranged from 2355 to 3130, while negative control sera lacked neutralization activity. IC₅₀ values for the mAb 10G6H5 ranged from 0.119 to 0.197μg/ml. The 80% neutralization titers (ID₈₀ or IC₈₀) were also similar among target cells with different levels of ACE2 or TMPRSS2. These findings indicate that levels of ACE2 and TMPRSS2 may not have a significant impact on neutralization titers for many antibodies.

**Assessment of neutralization specificity and range of antibody titers**

We assessed assay specificity and range of antibody titers using sera with reported neutralization titers, as well as 15 plasma samples from patients hospitalized with COVID-19. Thirty sera collected before 2019 served as negative controls, along with a negative control reference plasma standard (NIBSC #20/126) (Fig 6). Positive controls included the focused concordance samples comprising four high, five medium, and five low neutralizing antibody titers. All negative control sera failed to neutralize SARS-CoV-2 pseudoviruses at the lowest dilution tested.
Neutralization titers (ID_{50} and ID_{80}) segregated into high, medium, and low groupings, consistent with reported titers (Fig 6A and 6B). Plasma for patients hospitalized with acute COVID-19 showed a wide range of titers, consistent with previous reports [65]. We note, however, that the presence of reverse transcriptase or integrase inhibitors in sera or plasma samples from persons on anti-retroviral therapy (ART) has the potential to interfere with lentiviral pseudovirus readout that is dependent on reverse transcription and integration of the reporter gene. We therefore use lentiviral pseudoviruses bearing an envelope protein from amphotropic MLV or VSV as an additional control when assessing clinical samples that could include subjects on therapeutic or preventive ART. Non-specific inhibition of MLV- or VSV-pseudoviruses identifies sera that cannot be evaluated using this assay.

https://doi.org/10.1371/journal.pone.0248348.g004

Fig 4. Optimization of pseudovirus inoculum for neutralization assays. Neutralizations were performed in 293T-ACE2.TMPRSS2 cells with mAb 10G6H5 (A and C) and a rabbit serum against the S1 subunit (B and D) using various pseudovirus inoculums. X-axis indicates mAb concentration (A and C) and serum dilution (B and D) used. Y axis indicates percentage inhibition compared to pseudovirus infection without mAb or serum treatment.
Fig 5. ACE2 and TMPRSS2 levels at the cell surface. (A) Cell surface expression of ACE2 and TMPRSS2 on various cell types. (B) Mean fluorescence intensity (MFI) of ACE2 on various cell types compared to 293T cells X-axis indicates MFI and Y axis indicates various cell types analyzed. (C) Mean fluorescence intensity (MFI) of TMPRSS2 on various cell types compared to 293T cells. X-axis indicates MFI and Y axis indicates various cell types analyzed.

https://doi.org/10.1371/journal.pone.0248348.g005
Assessment of assay precision

To further qualify the assay performance, we assessed intermediate precision among three operators using blinded test samples that included the six NIBSC plasma standards, 15 sera samples from the focused concordance samples panel, and a blinded panel of 21 sera samples that was used in a survey to assess assay concordance among labs using various SARS-CoV-2 neutralization assays (https://dhvi.duke.edu/duke-team-implement-sars-cov-2-neutralization-assay-concordance-laboratories-worldwide). Neutralization titers giving 50% or 80% inhibition (ID$_{50}$ and ID$_{80}$, respectively) compared to control were used to calculate the %CV. Only positive samples (with at least 50% of titer results ≥ 1:40) were included in the precision calculation, which excluded six samples for ID$_{50}$ and 13 samples for ID$_{80}$. The overall %CV across all samples for ID$_{50}$ and ID$_{80}$ titers was 38.8% and 30.8%, respectively, when titers < 1:40 were imputed to be 1:20. We consider these results to be acceptable for a neutralization assay and adequate for most clinical studies. When titers <1:40 were excluded from the analysis, the %CV was 27.5% and 20.7%, respectively.

Table 1. Neutralization titers in 293T cells with low, medium, and high levels of ACE2 and TMPRSS2.

| Target cells (level) | Neutralization titer IC$_{50}$ or ID$_{50}$ (SD) | Neutralization titer IC$_{80}$ or ID$_{80}$ (SD) |
|----------------------|-----------------------------------------------|-----------------------------------------------|
|                      | Rabbit anti-RBD | Rabbit anti-S1 | NIBSC plasma | 10G6H5 (µg/ml) | NHS | Rabbit anti-RBD | Rabbit anti-S1 | NIBSC plasma | 10G6H5 (µg/ml) | NHS |
| 293T-ACE2, low       | 9377 (16)       | 6742 (2765)    | 3008 (651)    | 0.119 (0.025) | <40 | 3065 (22)       | 2053 (668)    | 789 (96)      | 0.467 (0.079) | <40 |
| 293T-ACE2, TMPRSS2, (low) | 9527 (87)     | 5663 (1302)    | 3130 (601)    | 0.166 (0.051) | <40 | 2915 (92)       | 1928 (179)    | 737 (93)      | 0.478 (0.153) | <40 |
| 293T-ACE2, TMPRSS2, (med) | 9542 (636)    | 5462 (765)     | 2893 (641)    | 0.197 (0.038) | <40 | 2903 (71)       | 1936 (135)    | 708 (74)      | 0.557 (0.111) | <40 |
| 293T-ACE2, TMPRSS2, (high) | 10540 (1508)  | 6652 (1649)    | 2355 (926)    | 0.163 (0.051) | <40 | 3271 (35)       | 2339 (515)    | 636 (257)     | 0.590 (0.112) | <40 |

NHS: Negative control human sera, SD: Standard deviation.

Fig 6. Neutralization titers of serum panels. ID$_{50}$ (A) and ID$_{80}$ (B) titers. ID$_{50}$ = inhibitory dilution leading to 50% neutralization compared to control. ID$_{80}$ = inhibitory dilution leading to 80% neutralization compared to control. X-axes indicate sample type. Y-axes indicate pseudovirus neutralization titers. Each dot represents an independent sample.

https://doi.org/10.1371/journal.pone.0248348.g006
Assessment of inter-laboratory agreement

We used the samples with reported neutralization titers as a benchmark for assessing accuracy of our assay. Although the reported titers were generated using different neutralization assay formats, we nevertheless found a strong correlation between our titers and the neutralization titers reported for the focused concordance samples (Fig 7A and 7B) and several NIBSC reference standards (Fig 7C and 7D). These results provide assurance that our assay provides titers that correlate well with titers measured in other assay formats.

Conclusion

We describe optimized procedures and detailed performance characteristics of an HIV-based, lentiviral pseudovirus neutralization assay for SARS-CoV-2 using a stable 293T cell line expressing ACE2 and TMPRSS2. The assay is quantitative, has a large dynamic range, and generates titers that correlate well with titers generated in other assays. The safety and relative
simplicity of the assay makes it a valuable and versatile tool for evaluating mAb potency and neutralizing antibody titers in a BSL-2 lab setting.

Supporting information
S1 Raw images. (TIF)

Acknowledgments
We thank the following for generously contributing materials for this study: Dr. David Montefiori (Duke University), the HIV Vaccine Trials Network, and the HIV Prevention Trials Network for the focused concordance samples; Dr. Michael Busch (Vitalant Research Institute) for the SNACS samples; Jesse Bloom and Katharine H. D. Crawford (Fred Hutchinson Cancer Center) for the 293T-ACE2 cells and plasmids. We also thank Dr. Carolyn A. Wilson (US Food and Drug Administration) for facilitating receipt of plasma samples from subjects hospitalized for COVID-19 and Drs. Konstantin Virnik and Ira Berkower (US Food and Drug Administration) for critical reading of the manuscript.

Author Contributions
Conceptualization: Sabari Nath Neerukonda, Russell Vassell, Wei Wang, Carol D. Weiss.
Formal analysis: Sabari Nath Neerukonda, Russell Vassell, Ye Yang, Tsai-Lien Lin, Wei Wang, Carol D. Weiss.
Funding acquisition: Carol D. Weiss.
Investigation: Sabari Nath Neerukonda, Russell Vassell, Rachel Herrup, Shufeng Liu, Tony Wang, Kazuyo Takeda, Wei Wang.
Methodology: Sabari Nath Neerukonda, Russell Vassell, Wei Wang.
Supervision: Carol D. Weiss.
Visualization: Kazuyo Takeda.
Writing – original draft: Sabari Nath Neerukonda.
Writing – review & editing: Wei Wang, Carol D. Weiss.

References
1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270–3. https://doi.org/10.1038/s41586-020-2012-7 PMID: 32015507
2. Gorbaliana AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology. 2020; 5(4):536–44. https://doi.org/10.1038/s41564-020-0695-z PMID: 32123347
3. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798):265–9. https://doi.org/10.1038/s41586-020-2008-3 PMID: 32015508
4. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China. 2019. New England Journal of Medicine. 2020; 382(8):727–33.
5. Poland GA, Ovsyannikova IG, Crooke SN, Kennedy RB. SARS-CoV-2 Vaccine Development: Current Status. Mayo Clinic Proceedings. 2020; 95(10):2172–88. https://doi.org/10.1016/j.mayocp.2020.07.021 PMID: 33012348
6. Noy-Porat T, Makdasi E, Alcalay R, Mechaly A, Levy Y, Bercovich-Kinori A, et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nature Communications. 2020; 11(1):4303. https://doi.org/10.1038/s41467-020-18159-4 PMID: 32855401

7. Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020; 584(7821):450–6. https://doi.org/10.1038/s41586-020-2571-7 PMID: 32691892

8. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences. 2020;202004168. https://doi.org/10.1073/pnas.2004168117 PMID: 32253318

9. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020; 323(16):1582–9. https://doi.org/10.1001/jama.2020.4783 PMID: 32219428

10. Manenti A, Maggetti M, Casa E, Martinuzzi D, Torelli A, Trombetta CM, et al. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples. Journal of Medical Virology. 2020; 92(10):2096–104. https://doi.org/10.1002/jmv.25986 PMID: 32383254

11. Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020; 130(9):4791–7. https://doi.org/10.1172/JCI140200 PMID: 32525844

12. Joyner MJ, Klassen SA, Senefeld J, Johnson PW, Carter RE, Wiggins CC, et al. Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy. medRxiv. 2020:2020.07.29.20162917.

13. Hartman W, Hess AS, Connor JP. Hospitalized COVID-19 patients treated with Convalescent Plasma in a mid-size city in the midwest. medRxiv. 2020;2020.06.19.20135830.

14. Jin C, Gu J, Yuan Y, Long Q, Zhang Q, Zhou H, et al. Treatment of Six COVID-19 Patients with Convalescent Plasma. medRxiv. 2020:2020.05.21.20109512.

15. Rasheed AM, Flak DF, Hashim HA, Mabood MF, Kabah KK, Almusawi YA, et al. The therapeutic effectiveness of Convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. medRxiv. 2020:2020.06.24.21269105.

16. Gharbharan A, Jordans CCE, GeurtsvanKessel C, den Hollande JG, Karim F, Mollema FPN, et al. Convalescent Plasma for COVID-19. A randomized clinical trial. medRxiv. 2020:2020.07.01.20139857.

17. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020; 26(7):1033–6. https://doi.org/10.1038/s41586-020-0913-5 PMID: 32398876

18. Caruana G, Croxatto A, Coste AT, Opota O, Lamoth F, Jaton K, et al. Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results. Clin Microbiol Infect. 2020. https://doi.org/10.1016/j.cmi.2020.06.019 PMID: 32593741

19. Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2. J Clin Microbiol. 2020; 58(6). https://doi.org/10.1128/JCM.00461-20 PMID: 32229605

20. Zettl F, Meister TL, Vollmer T, Fischer B, Steinmann J, Krawczyk A, et al. Rapid Quantification of SARS-CoV-2 Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. Vaccines (Basel). 2020; 8(3). https://doi.org/10.3390/vaccines8030386 PMID: 32679691

21. Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Eurosurveillance. 2020; 25(16):2000421. https://doi.org/10.2807/1560-7917.ES.2020.25.16.2000421 PMID: 32347204

22. Bohn MK, Lippi G, Horvath A, Sethi S, Koch D, Ferranti M, et al. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence. Clinical Chemistry and Laboratory Medicine (CCLM). 2020; 58(7):1037.

23. Özçürümez MK, Ambrosch A, Frey O, Haselmann V, Holdenrieder S, Kiehnthopf M, et al. SARS-CoV-2 antibody testing—questions to be asked. Journal of Allergy and Clinical Immunology. 2020; 146(1):35–43. https://doi.org/10.1016/j.jaci.2020.05.020 PMID: 32479758

24. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He W-t, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020; 369 (6506):956–63. https://doi.org/10.1126/science.abc7520 PMID: 32540903

25. Seydoux E, Homad LJ, MacCamy AJ, Parks KR, Hurburt NK, Jennewein MF, et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity. 2020; 53(1):98–105.e5. https://doi.org/10.1016/j.immuni.2020.06.001 PMID: 32561270
26. Wec AZ, Wrapp D, Herbert AS, Maurer DP, Haslwanter D, Sakharkar M, et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science. 2020; 369(6504):731–6. https://doi.org/10.1126/science.abc7424 PMID: 32540900

27. Coutard B, Vallee C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Research. 2020; 176:104742. https://doi.org/10.1016/j.antiviral.2020.104742 PMID: 32057769

28. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrell T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271–80.e8. https://doi.org/10.1016/j.cell.2020.02.052 PMID: 32142651

29. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. bioRxiv. 2020:2020.02.11.944462.

30. Zang R, Castro MFG, McCune BT, Zeng Q, Rothlauf PW, Sonnek NM, et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Science Immunology. 2020; 5(47):eabc3582. https://doi.org/10.1126/sciimmunol.abc3582 PMID: 32404436

31. Chen X, Li R, Pan Z, Qian C, Yang Y, You R, et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol. 2020; 17(6):647–9. https://doi.org/10.1038/s41423-020-0426-7 PMID: 32313207

32. Crawford KHD, Equina R, Dingens AS, Loes AN, Malone KD, Wolf CR, et al. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses. 2020; 12(5). https://doi.org/10.3390/v12050513 PMID: 32384820

33. Hyseni I, Molesti E, Benincasa L, Piu P, Casa E, Temperton NJ, et al. Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. Viruses. 2020; 12(9). https://doi.org/10.3390/v12091011 PMID: 32927639

34. Johnson MC, Lyddon TD, Suarez R, Salcedo B, LePique M, Graham M, et al. Optimized Pseudotyping Conditions for the SARS-CoV-2 Spike Glycoprotein. J Virol. 2020; 94(21). https://doi.org/10.1128/JVI.01062-20 PMID: 32788194

35. Lei C, Qian K, Li T, Zhang S, Fu W, Ding M, et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat Commun. 2020; 11(1):2070. https://doi.org/10.1038/s41467-020-16048-4 PMID: 32332763

36. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020; 5(4):562–9. https://doi.org/10.1038/s41564-020-0688-y PMID: 32094589

37. Miyakawa K, Jeremiah SS, Ohtake N, Matsunaga S, Yamaoka Y, Nishi M, et al. Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles. J Mol Cell Biol. 2020. https://doi.org/10.1093/jmcb/mjaa047 PMID: 32931563

38. Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, et al. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell. 2020; 182(5):1284–9.e9. https://doi.org/10.1016/j.cell.2020.07.012 PMID: 32730807

39. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020; 182(4):812–27.e19. https://doi.org/10.1016/j.cell.2020.06.043 PMID: 32697968

40. Oguntuyo KY, Stevens CS, Hung CT, Ikegame S, Acklin JA, Kowdle SS, et al. Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera. medRxiv. 2020. https://doi.org/10.1101/2020.08.13.20157222 PMID: 32817961

41. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020; 11(1):1620. https://doi.org/10.1038/s41467-020-15562-9 PMID: 32221306

42. Schmidt F, Weisblum Y, Muecksch F, Hoffmann HH, Michaillidis E, Lorenzi JCC, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020; 217(11).

43. Zheng Y, Larragoite ET, Lama J, Cisneros I, Delgado JC, Slev P, et al. Neutralization Assay with SARS-CoV-1 and SARS-CoV-2 Spike Pseudotyped Murine Leukemia Virions. bioRxiv. 2020. https://doi.org/10.1101/2020.07.17.207563 PMID: 32995778

44. Zhou L, Huntington K, Zhang S, Carlsen L, So EY, Parker C, et al. Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2 S pseudovirus infectivity by MEK inhibitor treatment of human cells. bioRxiv. 2020. https://doi.org/10.1101/2020.08.02.230839 PMID: 32793908
45. Naldini L, Blomer U, Gallay P, Orly D, Mulligan R, Gage FH, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996; 272(5259):263–7. https://doi.org/10.1126/science.272.5259.263 PMID: 8602510

46. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol. 1997; 15(8):871–5. https://doi.org/10.1038/nbt0997-871 PMID: 930402

47. Botcher E, Matrosovich T, Beyerle M, Klenk HD, Garten W, Matrosovich M. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J Virol. 2006; 80(19):9896–8. https://doi.org/10.1128/JVI.01118-06 PMID: 16973594

48. Lee JM, Huddleston J, Doud MB, Hooper KA, Wu NC, Bedford T, et al. Deep mutational scanning of hemagglutinin helps predict evolutionary fates of human H3N2 influenza variants. Proceedings of the National Academy of Sciences. 2018; 115(35):E8276–E85. https://doi.org/10.1073/pnas.1806133115 PMID: 30104379

49. Ravichandran S, Coyle EM, Klenow L, Tang J, Grubbs G, Liu S, et al. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. Sci Transl Med. 2020; 12(550). https://doi.org/10.1126/scitranslmed.abc3539 PMID: 32513867

50. Wang W, Anderson CM, De Feo CJ, Zhuang M, Yang H, Vassell R, et al. Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2. PLoS Pathog. 2011; 7(6):e1002081. https://doi.org/10.1371/journal.ppat.1002081 PMID: 21695241

51. Wang W, Butler EN, Veuquilla V, Vassell R, Thomas JT, Moos M Jr., et al. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J Virol Methods. 2008; 153(2):111–9. https://doi.org/10.1016/j.jviromet.2008.07.015 PMID: 18722473

52. Xie X, Muruato A, Lokugamage KG, Narayanan K, Zhang X, Zou J, et al. An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe. 2020; 27(5):841–8 e3. https://doi.org/10.1016/j.chom.2020.04.004 PMID: 32289263

53. De Feo CJ, Wang W, Hsieh ML, Zhuang M, Vassell R, Weiss CD. Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics. Retrovirology. 2014; 11:86. https://doi.org/10.1186/s12977-014-0086-8 PMID: 25274545

54. Wang W, Xie H, Ye Z, Vassell R, Weiss CD. Characterization of lentiviral pseudotypes with influenza hemagglutinin H5N1 and their performance in neutralization assays. J Virol Methods. 2010; 165(2):305–10. https://doi.org/10.1016/j.jviromet.2010.02.009 PMID: 20153374

55. Ou T, Mou H, Zhang L, Ojha A, Choe H, Farzan M. Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2. PLOS Pathogens. 2021; 17(1):e1009212. https://doi.org/10.1371/journal.ppat.1009212 PMID: 32637944

56. Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, et al. Cell entry mechanisms of SARS-CoV-2. Proceedings of the National Academy of Sciences. 2020; 117(21):11727–34. https://doi.org/10.1073/pnas.2003138117 PMID: 32376634

57. Yurkovetskiy L, Wang X, Pascal KE, Tomkins-Tinch C, Nyalile T, Wang Y, et al. SARS-CoV-2 Spike protein variant D614G increases infectivity and retains sensitivity to antibodies that target the receptor binding domain. bioRxiv: the preprint server for biology. 2020:2020.07.04.187757. https://doi.org/10.1101/2020.07.04.187757 PMID: 32637944

58. Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2020.

59. Giorgioli T, Cinati J, Rabenau H, Drosten C, Schwalbe H, Doerr HW, et al. Retroviral Vectors Pseudotyped with Severe Acute Respiratory Syndrome Coronavirus S Protein. Journal of Virology. 2004; 78(17):9007–15. https://doi.org/10.1128/JVI.78.17.9007-9015.2004 PMID: 15308697

60. Chu H, Chan JF-W, Yuen TT-T, Shuai H, Yuan S, Wang Y, et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. The Lancet Microbe. 2020; 1(1):e14–e23. https://doi.org/10.1016/S2666-5247(20)30004-5 PMID: 32835326

61. Matsuyma S, Nao N, Shirako K, Kawase M, Saito S, Takayama I, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proceedings of the National Academy of Sciences. 2020; 117(13):7001–3. https://doi.org/10.1073/pnas.2002589117 PMID: 32165541

62. Hoffmann M, Mösauer K, Hofmann-Winkler H, Kaul A, Kleine-Weber H, Krüger N, et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature. 2020; 585(7826):588–90. https://doi.org/10.1038/s41586-020-2575-3 PMID: 32698190
63. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271–80.e8. https://doi.org/10.1016/j.cell.2020.02.052 PMID: 32142651

64. Andrewes CH, Elford WJ. Observations on Anti-Phage Sera. I: “The Percentage Law”. Br J Exp Pathol. 1933; 14(6):367–76.

65. Salazar E, Kuchipudi SV, Christensen PA, Eagar T, Yi X, Zhao P, et al. Convalescent plasma anti–SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. The Journal of Clinical Investigation. 2020; 130(12). https://doi.org/10.1172/JCI141206 PMID: 32910806